BioGaia AB (BIOG-B.ST)

Overall impact
C (52)

Commentary

BioGaia AB is an average overall performer. With a 'C' rating of 52.2 for overall impact (46th percentile compared to all companies), BioGaia AB ranks 195th out of 229 industry peers, behind Nippon Shinyaku, Akorn, Lupin and 191 others, and ahead of PPD Incorporated, Endo International, Theratechnologies and 31 others. On top material causes for BioGaia AB's industry (Pharmaceuticals), BioGaia AB performs well in Equal Pay and Opportunity (80.8 score), Technology Innovation (82.0), Technology Innovation (82.0) and 9 other causes where it received an 'A' score and performs poorly in Humane Treatment of Animals (20.8 score), Reduced Use of tobacco (27.8), Sustainable Use of Water (30.3) and 9 other causes where it received a 'D' or 'F' score.
Impact
Cause BIOG-B.ST
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
1990
Employees
251
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Sweden
Share classes
BIOGY
ADR
BIOG-B.ST
Description
BioGaia AB (publ), a healthcare company, provides probiotic products worldwide. The company operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. The Adult Health segment provides gut health tablets, bone health tablets and oral health lozenges, as well as cultures, which are used as an ingredient in a licensee's dairy product. The Other segment provides packaging solutions. It sells its products through distribution partners or through its own distribution channels. BioGaia AB (publ) was founded in 1990 and is based in Stockholm, Sweden.
Material causes
Ethos considers the following causes material for BioGaia AB, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.